Ampliphi Biosciences (APHB) Price Target Increased to $6.00 by Analysts at HC Wainwright

Ampliphi Biosciences (NYSEAMERICAN:APHB) had its price objective lifted by HC Wainwright from $5.00 to $6.00 in a report published on Wednesday morning, Marketbeat reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.

Shares of Ampliphi Biosciences (NYSEAMERICAN:APHB) traded down $0.02 during midday trading on Wednesday, reaching $1.10. 328,394 shares of the company’s stock were exchanged, compared to its average volume of 1,787,192. Ampliphi Biosciences has a twelve month low of $0.67 and a twelve month high of $6.80. The company has a market capitalization of $10.64, a PE ratio of -0.11 and a beta of 2.93.

Ampliphi Biosciences (NYSEAMERICAN:APHB) last issued its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.37. Ampliphi Biosciences had a negative net margin of 2,050.00% and a negative return on equity of 31.85%.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at

About Ampliphi Biosciences

AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.

Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply